These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29437705)

  • 1.
    Dolgikh N; Hugle M; Vogler M; Fulda S
    Cancer Res; 2018 Apr; 78(8):2000-2013. PubMed ID: 29437705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-inhibition of BET proteins and PI3Kα triggers mitochondrial apoptosis in rhabdomyosarcoma cells.
    Boedicker C; Hussong M; Grimm C; Dolgikh N; Meister MT; Enßle JC; Wanior M; Knapp S; Schweiger MR; Fulda S
    Oncogene; 2020 May; 39(19):3837-3852. PubMed ID: 32161312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in
    Garcia N; Del Pozo V; Yohe ME; Goodwin CM; Shackleford TJ; Wang L; Baxi K; Chen Y; Rogojina AT; Zimmerman SM; Peer CJ; Figg WD; Ignatius MS; Wood KC; Houghton PJ; Vaseva AV
    Mol Cancer Ther; 2022 Jan; 21(1):170-183. PubMed ID: 34737198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.
    Graab U; Hahn H; Fulda S
    Oncotarget; 2015 Apr; 6(11):8722-35. PubMed ID: 25749378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
    Ascierto PA; Schadendorf D; Berking C; Agarwala SS; van Herpen CM; Queirolo P; Blank CU; Hauschild A; Beck JT; St-Pierre A; Niazi F; Wandel S; Peters M; Zubel A; Dummer R
    Lancet Oncol; 2013 Mar; 14(3):249-56. PubMed ID: 23414587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells.
    Laszig S; Boedicker C; Weiser T; Knapp S; Fulda S
    Cancer Lett; 2020 Aug; 486():46-57. PubMed ID: 32445837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
    Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
    Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
    Haydn T; Metzger E; Schuele R; Fulda S
    Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
    Ramakrishnan VG; Miller KC; Macon EP; Kimlinger TK; Haug J; Kumar S; Gonsalves WI; Rajkumar SV; Kumar SK
    Haematologica; 2019 Oct; 104(10):2061-2074. PubMed ID: 30846494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcoma.
    Nakagawa N; Kikuchi K; Yagyu S; Miyachi M; Iehara T; Tajiri T; Sakai T; Hosoi H
    Biochem Biophys Res Commun; 2019 May; 512(3):524-530. PubMed ID: 30904164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
    Yohe ME; Gryder BE; Shern JF; Song YK; Chou HC; Sindiri S; Mendoza A; Patidar R; Zhang X; Guha R; Butcher D; Isanogle KA; Robinson CM; Luo X; Chen JQ; Walton A; Awasthi P; Edmondson EF; Difilippantonio S; Wei JS; Zhao K; Ferrer M; Thomas CJ; Khan J
    Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.
    Wada M; Horinaka M; Yamazaki T; Katoh N; Sakai T
    PLoS One; 2014; 9(11):e113217. PubMed ID: 25422890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
    Hebron KE; Wan X; Roth JS; Liewehr DJ; Sealover NE; Frye WJE; Kim A; Stauffer S; Perkins OL; Sun W; Isanogle KA; Robinson CM; James A; Awasthi P; Shankarappa P; Luo X; Lei H; Butcher D; Smith R; Edmondson EF; Chen JQ; Kedei N; Peer CJ; Shern JF; Figg WD; Chen L; Hall MD; Difilippantonio S; Barr FG; Kortum RL; Robey RW; Vaseva AV; Khan J; Yohe ME
    Clin Cancer Res; 2023 Jan; 29(2):472-487. PubMed ID: 36322002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
    Odeniyide P; Yohe ME; Pollard K; Vaseva AV; Calizo A; Zhang L; Rodriguez FJ; Gross JM; Allen AN; Wan X; Somwar R; Schreck KC; Kessler L; Wang J; Pratilas CA
    Oncogene; 2022 May; 41(21):2973-2983. PubMed ID: 35459782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer.
    Xu YC; Wang X; Chen Y; Chen SM; Yang XY; Sun YM; Geng MY; Ding J; Meng LH
    Theranostics; 2017; 7(4):974-986. PubMed ID: 28382169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis.
    Heinicke U; Kupka J; Fulda S
    Oncotarget; 2015 Nov; 6(35):37836-51. PubMed ID: 26473375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK targeting in N-RAS mutated metastatic melanoma.
    Thumar J; Shahbazian D; Aziz SA; Jilaveanu LB; Kluger HM
    Mol Cancer; 2014 Mar; 13():45. PubMed ID: 24588908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.